NeOnc Technologies (NASDAQ:NTHI), a clinical-stage CNS oncology company, is drawing increased attention from Wall Street, insiders, and institutions. Maxim Group, Alliance Global Partners, and BTIG Research have initiated coverage with favorable ratings and targets.
CEO Amir Heshmatpour has bought over $500,000 in recent shares, with insider purchases nearing $1 million in a year. Institutional investors such as Bank of America, State Street, and Barclays have raised positions. Lead candidate NEO100 is in a fully enrolled Phase 2a trial for aggressive brain tumors, including glioblastoma, with interim data expected soon. NeOnc is also advancing NEO212, a hybrid CNS therapeutic, leveraging proprietary intranasal delivery designed to bypass the blood-brain barrier.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
- Multiple firms (Maxim, Alliance Global Partners, BTIG) initiated coverage with favorable ratings and targets
- CEO Amir Heshmatpour recently purchased over $500,000 of shares; insider buys near $1 million in a year
- Institutional investors including Bank of America, State Street, and Barclays increased positions
- Lead asset NEO100 in fully enrolled Phase 2a trial for aggressive brain tumors, including glioblastoma
- Interim Phase 2a data for NEO100 expected in the near term
- Pipeline includes NEO212, a hybrid CNS therapeutic with potential across multiple malignancies and conditions
Recent insider buying More than $500,000 CEO open‑market share purchases in recent weeks
Cumulative insider purchases Approaching $1 million Insider buying over the past year
NEO100 trial stage Phase 2a Fully enrolled trial in aggressive brain tumors such as glioblastoma
NEO212 status Hybrid therapeutic candidate In development for multiple CNS malignancies and neurological conditions
Current share price $5.34 Trading before publication of this article
52-week range $3.20 – $12.99 Low and high prior to this news
$5.34 Last Close
Volume Volume 39,329 is below 20-day average 114,531 (relative volume 0.34) ahead of this positive-leaning article. low
Technical Shares at $5.34 are trading below the 200-day MA of $8.24 and sit 58.89% under the 52-week high of $12.99.
NTHI was down about 1.5% while key biotech peers showed mixed moves: large declines in ELTX (-10.14%), CCCC (-8.78%), KYTX (-8.57%), TRDA (-7.39%) and a gain in IPHA (+3.21%), pointing to stock-specific dynamics rather than a unified sector move.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Q1 2026 earnings | Negative | -2.9% | Reported Q1 2026 net loss and very limited cash runway alongside clinical updates. |
| May 07 | Insider & pipeline focus | Positive | +22.2% | Coverage on insider buying, NEO100 Phase 2a progress, and delivery-platform potential. |
| May 06 | Insider conviction piece | Positive | +6.4% | Article spotlighting CEO’s ~$1M insider buys and imminent NEO100 catalyst. |
| May 05 | Insider buying update | Positive | +20.5% | Company announcement of >$500K recent insider purchases and NEO100/NEO212 milestones. |
| Apr 14 | 2025 results & buys | Neutral | +1.7% | 2025 financial review with $62M net loss and ~$300K insider purchases plus catalysts. |
Pattern Detected
Recent news tied to insider buying and clinical progress has generally seen positive price reactions, while a detailed Q1 2026 update with losses and low cash coincided with a negative move.
Recent Company History
Over the last few months, NeOnc has repeatedly highlighted insider buying and advancing brain cancer programs. Articles on CEO Amir Heshmatpour’s purchases of over $500,000 and nearly $1 million cumulatively, plus fully enrolled NEO100 Phase 2a data expected around August 2026, were followed by strong gains of 6–22%. Earnings-related updates showed larger net losses and limited cash, with a Q1 2026 report and going-concern commentary preceding a -2.91% move. Today’s article echoes the insider and institutional accumulation themes seen in several of those prior, positively received pieces.
An effective S-3 dated April 10, 2026 registers 680,558 shares of Common Stock for resale by selling stockholders, including 340,279 issued shares and 340,279 warrant shares at a $9.00 exercise price. The company receives no proceeds from resales but may receive cash if warrants are exercised.
This announcement emphasizes expanding analyst coverage, notable insider buying of more than $500,000 (approaching $1 million over a year), and institutional participation as NeOnc advances NEO100 into a fully enrolled Phase 2a trial for glioblastoma. Recent SEC filings, however, highlighted a quarterly net loss of $8.8 million and low cash, alongside an effective S‑3 for 680,558 resale shares. Investors may watch upcoming NEO100 data timing, additional financing steps, and ongoing insider activity as key markers.
central nervous system medical
“a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers”
The central nervous system (CNS) is the body’s main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
glioblastoma medical
“Phase 2a clinical trial targeting aggressive brain tumors such as glioblastoma”
Glioblastoma is a fast-growing and aggressive type of brain tumor that can affect a person’s thinking, movement, or senses. Its seriousness and difficulty to treat can lead to significant health impacts, making it a concern for medical research and drug development. For investors, advances or setbacks in glioblastoma treatments can influence biotech companies and healthcare markets focused on cancer therapies.
intranasal drug delivery medical
“developing proprietary intranasal drug delivery technologies designed to bypass the blood-brain barrier”
Intranasal drug delivery is a method of giving medication through the nose so the active ingredient is absorbed across the nasal lining into the bloodstream or, in some cases, more directly into the brain. For investors, it matters because this route can speed onset, avoid breakdown in the digestive system, and enable treatments that would be hard or costly by injection or pills, potentially shortening development time, cutting costs, and opening new market opportunities.
blood-brain barrier medical
“technologies designed to bypass the blood-brain barrier, one of the most significant challenges”
A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.
phase 2a medical
“NEO100, is being evaluated in a fully enrolled Phase 2a clinical trial”
Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.
AI-generated analysis. Not financial advice.
Alliance Global Partners and Maxim Group Initiate Separate NeOnc Technologies Coverage with Favorable Ratings
DENVER, May 19, 2026 (GLOBE NEWSWIRE) — (www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.
Maxim Group and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company’s current market position. BTIG Research also recently launched coverage with a advantageous rating and target, reflecting increasing analyst interest in NeOnc’s differentiated CNS-focused platform.
Investor confidence has been reinforced by substantial insider buying activity. Amir Heshmatpour, the company’s CEO, Chairman, and President, has consistently purchased shares on the open market, with recent acquisitions totaling more than
Institutional ownership has also continued to expand. Recent filings show multiple firms increasing their positions in the company, including Bank of America, State Street Corp, Barclays PLC, Westmount Partners, and Foundations Investment Advisors. While the dollar amounts vary, the continued accumulation by both institutional investors and insiders is viewed by some market participants as notable given the company’s stage of development and upcoming catalysts.
NeOnc is currently developing proprietary intranasal drug delivery technologies designed to bypass the blood-brain barrier, one of the most significant challenges in neuro-oncology. Its lead candidate, NEO100, is being evaluated in a fully enrolled Phase 2a clinical trial targeting aggressive brain tumors such as glioblastoma, with interim data expected in the near term. The company is also advancing NEO212, a hybrid therapeutic candidate that may have applications across multiple CNS malignancies and neurological conditions.
The convergence of analyst coverage, insider accumulation, institutional participation, and approaching clinical milestones has increased visibility around the company as it continues development of its CNS oncology platform.
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.
Sources and Links;
- NeOnc Technologies Insider Buying & Pipeline Update: https://www.sec.gov/edgar
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/
For further information, please visit 247marketnews.com.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
What recent analyst coverage has NeOnc Technologies (NASDAQ:NTHI) received in May 2026?
NeOnc Technologies has recently received new analyst coverage with favorable ratings and price targets. According to NeOnc Technologies, Maxim Group, Alliance Global Partners, and BTIG Research all initiated coverage, highlighting perceived benefit potential of the CNS-focused platform relative to the company’s current market position.
How much NeOnc Technologies (NTHI) stock has CEO Amir Heshmatpour recently bought?
CEO Amir Heshmatpour has recently purchased more than $500,000 of NeOnc Technologies shares. According to NeOnc Technologies, cumulative insider purchases over the past year are approaching $1 million, with buying activity occurring ahead of anticipated clinical milestones and upcoming data readouts.
Which institutional investors have increased positions in NeOnc Technologies (NTHI)?
Several large institutions have increased their positions in NeOnc Technologies shares. According to NeOnc Technologies, recent filings show higher holdings from Bank of America, State Street Corp, Barclays PLC, Westmount Partners, and Foundations Investment Advisors, with varying dollar amounts across these firms.
What is NeOnc Technologies’ NEO100 Phase 2a trial for glioblastoma?
NEO100 is NeOnc Technologies’ lead candidate in a fully enrolled Phase 2a trial. According to NeOnc Technologies, the study targets aggressive brain tumors such as glioblastoma, using proprietary intranasal delivery designed to bypass the blood-brain barrier, with interim data expected in the near term.
What role does NEO212 play in NeOnc Technologies’ CNS oncology pipeline?
NEO212 is a hybrid therapeutic candidate within NeOnc Technologies’ CNS-focused platform. According to NeOnc Technologies, NEO212 may have applications across multiple central nervous system malignancies and neurological conditions, complementing NEO100 and leveraging the company’s emphasis on brain-targeted drug delivery.
Why are upcoming clinical milestones important for NeOnc Technologies (NTHI) investors?
Upcoming clinical milestones may provide key data on NeOnc Technologies’ brain cancer candidates. According to NeOnc Technologies, interim Phase 2a results for NEO100 and continued progress with NEO212, combined with insider and institutional accumulation, are drawing increased visibility to the CNS oncology platform.
